Miltefosine: oral treatment of leishmaniasis

References

• Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health6(11), 849–854 (2001).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Soto P et al. Respuesta a antimoniales pentavalentes para el tratamiento de la leishmaniasis cutánea en Colombia. Rev. Asoc. Col. Dermatol. Cir. Dermatol.13(1), 39–44 (2005).
   Google Scholar
• Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J. Med. Res.120(3), 166–172 (2004).
   PubMed Web of Science ®Google Scholar
• Sundar S, More D, Singh M et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis.31, 1104–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Abdo M, Elamin W, Khalil E, Mukhtar M. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East Mediterr. Health J.9(4), 837–843 (2003).
   PubMedGoogle Scholar
• Rijal S, Chappuis F, Singh R et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg.97(3), 350–354 (2003).
   PubMed Web of Science ®Google Scholar
• Costa J, Garcia A, Rêbelo J, Guimarães K, Guimarães R, Nunes P. Óbito durante tratamento da leishmaniose tegumentar americana com stibogluconato de sódio bp 88® (shandong xinhua). Rev. Soc. Bras. Med. Trop.36(2), 295–298 (2003).
   PubMedGoogle Scholar
• Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans. R. Soc. Trop. Med. Hyg.97(5), 597–598 (2003).
   PubMed Web of Science ®Google Scholar
• Soto J, Valda-Rodriquez L, Toledo J et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.71(5), 577–581 (2004).
   PubMed Web of Science ®Google Scholar
• Croft S, Neal R, Pendergast W, Chan J. The activity of alkyl phosphocholines and related derivates against Leishmania donovani. Biochem. Pharmacol.36, 2633–2636 (1987).
   PubMed Web of Science ®Google Scholar
• Murray H. Treatment of visceral leishmaniasis in 2004. Am. J. Trop. Med. Hyg.71(6), 787–794 (2004).
   PubMed Web of Science ®Google Scholar
• Berman J. Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr. Infect. Dis. Rep.7(1), 33–38 (2005).
   PubMedGoogle Scholar
• Murray H. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev. Anti Infect. Ther.2(2), 279–292 (2004).
   PubMedGoogle Scholar
• Prasad R, Kumar R, Jaiswal B, Singh U. Miltefosine: an oral drug for visceral leishmaniasis. Indian J. Pediatr.71(2), 143–144 (2004).
   PubMedGoogle Scholar
• Sangraula H, Sharma K, Rijal S, Dwivedi S, Koirala S. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. J. Assoc. Physicians India51, 686–690 (2003).
   PubMedGoogle Scholar
• Murray H, Berman J, Davies C, Saravia N. Advances in leishmaniasis. Lancet366, 1561–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg.95(3), 239–4318 (2001).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis.27, 305–318 (2004).
   PubMed Web of Science ®Google Scholar
• Davies C, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad. Saude Publica16(4), 925–950 (2000).
   PubMedGoogle Scholar
• Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg.46(3), 296–306 (1992).
   PubMed Web of Science ®Google Scholar
• Soto J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis.16, 417–425 (1993).
   PubMed Web of Science ®Google Scholar
• Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg.50, 107–111 (1994).
   PubMed Web of Science ®Google Scholar
• Lightburn E, Morand JJ, Meynard JB et al. Thérapeutique des leishmanioses tégumentaires du Nouveau Monde. Expérience à propos de 320 cas traités par isethionate de pentamidine à fortes doses. Med. Trop.63, 35–44 (2003).
   PubMedGoogle Scholar
• Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.88, 695–698 (1994).
   PubMed Web of Science ®Google Scholar
• Hendrickx E, Agudelo S, Munoz D, Puerta J, Velez Bernal I. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am. J. Trop. Med. Hyg.59(6), 889–892 (1998).
   PubMed Web of Science ®Google Scholar
• Berman J. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis.24, 684–703 (1997).
   PubMed Web of Science ®Google Scholar
• Velez I, Agudelo S, Hendrickx E et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med.126, 232–236 (1997).
   PubMed Web of Science ®Google Scholar
• Osorio L, Palacios R, Chica M, Ochoa M. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet351, 498–499 (1998).
   PubMed Web of Science ®Google Scholar
• Hay R. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br. J. Dermatol.141(Suppl. 56), 36–40 (1999).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Gutierrez P et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase 2 pilot study. Am. J. Trop. Med. Hyg.66(2), 147–151 (2002).
   PubMed Web of Science ®Google Scholar
• Gamier T, Croft S. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs3(4), 538–544 (2002).
   PubMedGoogle Scholar
• Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/methyl-benzethonium chloride plus parenteral meglumine antimonite as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis.26, 56–58 (1998).
   PubMed Web of Science ®Google Scholar
• Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol. Ther.66, 39–82 (1995).
   PubMed Web of Science ®Google Scholar
• Croft SL, Seifert K, Duchene M. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol.126(2), 165–172 (2003).
   PubMed Web of Science ®Google Scholar
• Westphal O. Ether lipids in oncology – welcoming address. Lipids22, 787–788 (1987).
   PubMed Web of Science ®Google Scholar
• Herrmann H, Gercken G. Metabolism of 1-O-[1´-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond. Mol. Biochem. Parasitol.5, 65–76 (1982).
   PubMed Web of Science ®Google Scholar
• Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother.36, 1630–1634 (1992).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rosenkaimer F, Makharia M et al. Trial of miltefosine for visceral leishmaniasis. Lancet352, 1821–1823 (1998).
   PubMed Web of Science ®Google Scholar
• Murray H. Suppression of post-treatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother.44, 3235–3236 (2000).
   PubMed Web of Science ®Google Scholar
• Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother.45, 1872–1875 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.93, 85–90 (1999).
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft S, De Doncker S et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg.73, 272–275 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufmann-Kolle P, Drevs J, Berger M et al. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol.34(5), 393–398 (1994).
   PubMed Web of Science ®Google Scholar
• Achterberg V, Gercken G. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol.26, 277–287 (1987).
   PubMed Web of Science ®Google Scholar
• Pronk L, Planting A, Oosterom R, Drogendijk T, Stoter G, Verweij J. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur. J. Cancer30A(7), 1019–1022 (1994).
   PubMed Web of Science ®Google Scholar
• Soto J, Arana B, Toledo J et al. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis.38(9), 1266–1272 (2004).
   PubMed Web of Science ®Google Scholar
• Theischen M, Bornfeld N, Becher R, Kellner U, Wessing A. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium. Ger. J. Ophthalmol.2(2), 113–115 (1993).
   PubMedGoogle Scholar
• Berman J. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother.6(8), 1381–1388 (2005).
   PubMed Web of Science ®Google Scholar
• Sundar S. Treatment of visceral leishmaniasis. Med. Microbiol. Immunol. (Berl.)190(1–2), 89–92 (2001).
   PubMed Web of Science ®Google Scholar
• Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J. Infect. Chemother.10(6), 307–315 (2004).
   PubMedGoogle Scholar
• Croft S, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des.8(4), 319–342 (2002).
   PubMed Web of Science ®Google Scholar
• Wieder T, Perlitz C, Wieprecht M, Huang R, Geilen C, Orfanos C. Two new sphingomyelin analogues inhibit phosphatidylcholine biosynthesis by decreasing membrane-bound CTP: phosphocholine cytidylyltransferase levels in HaCaT cells. Biochem. J.311(Pt 3), 873–879 (1995).
   PubMed Web of Science ®Google Scholar
• Paris C, Loiseau P, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother.48(3), 852–859 (2004).
   PubMed Web of Science ®Google Scholar
• Welburn S, Lillico S, Murphy N. Programmed cell death in procyclic form Trypanosoma brucei rhodesiense: identification of differentially expressed genes during Con A induced death. Mem. Inst. Oswaldo Cruz94, 229–234 (1999).
   PubMedGoogle Scholar
• Wieder T, Reutter W, Orfanos C, Geilen C. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res.38(3), 249–259 (1999).
   PubMed Web of Science ®Google Scholar
• Wright M, Howe A, Zaremberg V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem. Cell Biol.82(1), 18–26 (2004).
   PubMedGoogle Scholar
• Cui Z, Houweling M. Phosphatidylcholine and cell death. Biochim. Biophys. Acta1585(2–3), 87–96 (2002).
   PubMed Web of Science ®Google Scholar
• Lux H, Heise N, Klenner T, Hart D, Opperdoes F. Ether-lipid (alkyl-phospholipid analog) metabolism and the mechanism of action of etherlipid analogs in Leishmania. Mol. Biochem. Parasitol.111, 1–14 (2000).
   PubMed Web of Science ®Google Scholar
• Lira R, Contreras L, Santa-Rita R, Urbina J. Mechanism of action of antiproliferative alkyl-lysophospholipids against the protozoan parasite Trypanosoma cruzi. Potentiation of in vitro activity by the sterol biosynthesisinhibitor ketoconazole. J. Antimicrob. Chemother.47, 537–546 (2001).
   PubMed Web of Science ®Google Scholar
• Santa-Rita R, Lira R, Barbosa H, Urbina J, de Castro S. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J. Antimicrob. Chemother.55(5), 780–784 (2005).
   PubMed Web of Science ®Google Scholar
• Sundar S, Gupta L, Makharia M, Singh M, Voss A, Rosenkaimer F. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol.93, 589–597 (1999).
   PubMed Web of Science ®Google Scholar
• Sundar S, Makharia A, More DK et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis.31, 1110–1113 (2000).
   PubMed Web of Science ®Google Scholar
• Jha T, Sundar S, Thakur C, Bachmann P, Karbwang J, Fischer C. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med.341, 1795–1800 (1999).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha T, Thakur C, Engel J, Sindermann H, Fischer C. Miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med.347, 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• Program CTC. Common Toxicity Criteria. National Cancer Institute, MD, USA (2002).
   Google Scholar
• Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J.22, 434–438 (2003).
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Jha T, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis.38, 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez S, Gonzalez M, Vernaza M. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin. Infect. Dis.24(2), 165–169 (1997).
   PubMed Web of Science ®Google Scholar
• Martinez S, Marr J. Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl. J. Med.326(11), 741–744 (1992).
   PubMed Web of Science ®Google Scholar
• Palacios R, Osorio LE, Grajalew LF, Ochoa M. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg.64(3–4), 187–193 (2001).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Vega J, Berman J. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.72(4), 421–422 (2005).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis.33(7), E57–E61 (2001).
   PubMedGoogle Scholar
• Sindermann H, Engel KR, Fischer C, Bommer W; Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis.39(10), 1520–1523 (2004).
   PubMed Web of Science ®Google Scholar
• Schraner C, Hasse B, Hasse U et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin. Infect. Dis.40(12), e120–e124 (2005).
   PubMed Web of Science ®Google Scholar
• Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis.2(8), 494–501 (2002).
   PubMed Web of Science ®Google Scholar
• Pink R, Hudson A, Mouries MA, Bendig M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov.4(9), 727–740 (2005).
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and antileishmanial drugs. Antimicrob. Agents Chemother.50, 73–79 (2006).
   PubMed Web of Science ®Google Scholar
• Zerpa O, Blanco B, Diaz N, Tapia F, Convit J. Miltefosine in the treatment of diffuse cutaneous leishmaniasis. Third World Congress on Leishmaniasis. Book of Abstracts, 344 (2005).
   Google Scholar
• Reithinger R, Leslie T, Mohsen M et al. A randomized controlled trial to test the efficacy of miltefosine against Leishmania tropica in Kabul, Afghanistan. Third World Congress on Leishmaniasis. Book of Abstracts, 49 (2005).
   Google Scholar